Education
About Us
Working with TipRanks
Follow Us
Lemaitre Vascular (LMAT)
:LMAT
Earnings Data
Report Date
Feb 19, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
0.66Last Year’s EPS
0.49Same Quarter Last Year
Moderate Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook. LeMaitre Vascular reported strong organic sales growth, international expansion success, and improved gross margins, but faced challenges related to a catheter recall, struggles in the APAC region, and a lowered revenue guidance due to FX changes. The sentiment is balanced with positive achievements and notable challenges.Company Guidance
Strong Organic Sales Growth
LeMaitre Vascular reported an organic sales growth of 12% in Q3 2025, with a notable increase in gross margin. This growth was primarily led by Grafts (up 23%) and Shunts (up 18%).
International Expansion Success
The international launch of Artegraft exceeded expectations with Q3 sales at $1.4 million and projected Q4 sales of $2 million. Artegraft grew 33% worldwide in Q3.
Record Gross Margin and Operating Income
Adjusted gross margin increased to 70.8%, driven by higher pricing, manufacturing efficiencies, and product mix. Adjusted operating income rose 29%, resulting in an adjusted operating margin of 28%.
Robust Cash Flow and Financial Position
LeMaitre ended Q3 with $343.1 million in cash and securities, generating $28.8 million in cash from operations and paying $4.5 million in dividends to shareholders.
Positive Pricing Strategy
The company implemented an 8% price increase for U.S. hospitals for 2026, with 55% of North American revenue now subject to price floors.
European Regulatory Approvals
LeMaitre received German approval for RestoreFlow and anticipates further EU approvals, accelerating international market entry.
LMAT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
LMAT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 06, 2025 | $85.60 | $86.82 | +1.43% |
Aug 05, 2025 | $85.42 | $93.04 | +8.92% |
May 01, 2025 | $89.84 | $78.35 | -12.79% |
Feb 27, 2025 | $99.22 | $91.21 | -8.07% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Lemaitre Vascular (LMAT) report earnings?
Lemaitre Vascular (LMAT) is schdueled to report earning on Feb 19, 2026, After Close (Confirmed).
What is Lemaitre Vascular (LMAT) earnings time?
Lemaitre Vascular (LMAT) earnings time is at Feb 19, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LMAT EPS forecast?
LMAT EPS forecast for the fiscal quarter 2025 (Q4) is 0.66.